This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ma, L. Articles by Kerbel, R. S. Search for Related Content PubMed PubMed Citation Articles by Ma, L. Articles by Kerbel, R. S.

In vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy

¹ Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre and Department of Medical Biophysics, University of Toronto, ² Molecular Biology and Cancer, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada; ³ ImClone Systems, Inc., New York, New York, and ⁴ McMaster University, Henderson Research Centre, Hamilton, Ontario, Canada

Requests for reprints: Robert S. Kerbel, Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, S-217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Phone: 416-480-5711; Fax: 416-480-5703; E-mail: kerbel{at}srcl.sunnybrook.utoronto.ca.

One of the emerging problems concerning the use of antiangiogenic drugs, when used in combination with certain chemotherapy regimens, is enhanced rates and severity of adverse clotting events. For as yet unknown reasons, certain drugs and particular combinations can induce an elevated incidence of thromboembolic events in treated cancer patients [e.g., SU5416, a vascular endothelial cell growth factor receptor-2 (VEGFR-2) antagonist, when combined with gemcitabine and cisplatin (CDDP)]. Such results highlight the need to develop assays capturing the essence of enhanced clot formation under such combination treatment and which may have predictive potential as well. Here, we report the possibility of such an assay (i.e., the ratio of tissue factor over tissue factor pathway inhibitor expression or activity in cultured human endothelial cells calculated as a coagulation index). A marked increase in coagulation index was observed after exposure to SU5416 and the CDDP/gemcitabine chemotherapy combination in contrast to either of these treatments used alone. Substitution of SU5416 with any one of ZD6474, SU6668, IMC-1121, a monoclonal antibody to VEGFR-2, or an antibody to VEGF (bevacizumab) did not cause a marked increase in the coagulation index, nor did the combination of SU5416 with 5-fluorouracil and leucovorin. Finally, we noted that reducing the concentrations of gemcitabine and CDDP (i.e., use of "metronomic dosing" in vitro) significantly attenuated the coagulation index increase induced by these drugs, suggesting that use of low-dose chemotherapy regimens might be an approach to consider for reducing the incidence of adverse clotting events associated with chemotherapy alone or in conjunction with antiangiogenic drug combination therapies.

This article has been cited by other articles:

				R. S. Kasthuri, M. B. Taubman, and N. Mackman Role of Tissue Factor in Cancer J. Clin. Oncol., October 10, 2009; 27(29): 4834 - 4838. [Abstract] [Full Text] [PDF]

				J. Yu, L. May, C. Milsom, G. M. Anderson, J. I. Weitz, J. P. Luyendyk, G. Broze, N. Mackman, and J. Rak Contribution of Host-Derived Tissue Factor to Tumor Neovascularization Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1975 - 1981. [Abstract] [Full Text] [PDF]

				G. Francia, U. Emmenegger, C. R. Lee, Y. Shaked, C. Folkins, M. Mossoba, J. A. Medin, S. Man, Z. Zhu, L. Witte, et al. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using {beta}-human choriogonadotropin secreting tumor cell lines Mol. Cancer Ther., October 1, 2008; 7(10): 3452 - 3459. [Abstract] [Full Text] [PDF]

				B. Laquente, C. Lacasa, M. M. Ginesta, O. Casanovas, A. Figueras, M. Galan, I. G. Ribas, J. R. Germa, G. Capella, and F. Vinals Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model Mol. Cancer Ther., March 1, 2008; 7(3): 638 - 647. [Abstract] [Full Text] [PDF]

				J. Gien, G. J. Seedorf, V. Balasubramaniam, N. Markham, and S. H. Abman Intrauterine Pulmonary Hypertension Impairs Angiogenesis In Vitro: Role of Vascular Endothelial Growth Factor Nitric Oxide Signaling Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1146 - 1153. [Abstract] [Full Text] [PDF]

				J. Woodley-Cook, L. Y.Y. Shin, L. Swystun, S. Caruso, S. Beaudin, and P. C. Liaw Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway Mol. Cancer Ther., December 1, 2006; 5(12): 3303 - 3311. [Abstract] [Full Text] [PDF]

				R. S. Kerbel Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science, May 26, 2006; 312(5777): 1171 - 1175. [Abstract] [Full Text] [PDF]

				U. Emmenegger and R. S. Kerbel A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs Clin. Cancer Res., November 1, 2005; 11(21): 7589 - 7592. [Full Text] [PDF]